Levine JH, Michael JR, Guarnieri T.Multifocal atrial tachycardia: A toxic effect of theophylline. Lancet1985; 1: 12-14.
2.
Woodcock AA, Johnson MA, Geddes DMTheophylline prescribing, serum concentrations, and toxicity. Lancet1983; 2: 610-613.
3.
Greening AP, Baillie E., Pride NBSustained release oral aminophylline in patients with airflow obstruction . Thorax1981; 36: 303-307.
4.
Aronson JK, Hardman M., Reynolds Djm.ABC of monitoring drug therapy. Theophylline. British Medical Journal1992; 305: 1355 -1358.
5.
Bukowskyj M. , Nakatsku K., Munt PWTheophylline reassessed. Annals of Internal Medicine1984; 101: 63 - 73.
6.
Hendeles L., Weinberger M.Theophylline: a 'state of the art' review. Pharmacotherapy1983; 3: 2-44.
7.
Jacobs MH, Senior RM, Kessler G.Clinical experience with theophylline. Relationships between dosage, serum concentration and toxicity. Journal of the American Medical Association1976; 235: 1983-1986.
8.
Jenne JW, Wyze E., Rood FS, MacDonald FMPharmacokinetics of theophylline. Applications to adjustment of the clinical dose of aminophylline. Clinical Pharmacology and Therapeutics1972; 13: 349-360.
9.
Josephson GW , Kennedy HL, MacKenzie EJ, Gibson G.Cardiac dysrhythmias during treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol . Chest1980; 78: 429-435.
10.
Ogilvie RI, Fernandez PG, Winsberg F.Cardiovascular response to increasing theophylline concentrations. European Journal of Clinical Pharmacology1977; 2: 409-414.
11.
Zandvoort FA et al. Theophylline and serum electrolytes. Annals of Internal Medicine1986; 104: 134-135.
12.
Hendeles L., Jenkins J., Temple R.Revised FDA labeling guidelines for theophylline oral dosage forms. Pharmacotherapy1995; 15: 409-426.
13.
Burgan Ths, Gupta I., Bate CMFatal overdose of theophylline simulating acute pancreatitis. British Medical Journal1982; 284: 939-940.
14.
Eason J., Markowe Hlj.Aminophylline toxicity- how many hospital deaths does it cause? Respiratory Medicine1989; 83: 219-226.
15.
Henderson A. , Wright DM, Pond SMManagement of theophylline overdose patients in the Intensive Care Unit. Anaesthesia and Intensive Care1992; 20: 56-62.
16.
Gaudreault P., Guay J.Theophylline poisoning. Pharmacological considerations and management. Medical Toxicology1986; 1: 169-191.
17.
Helliwell M. , Berry D.Theophylline poisoning in adults. British Medical Journal1979; 2: 1114.
18.
Jefferys DB et al. Haemoperfusion for theophylline overdose . British Medical Journal1980; 280: 1167.
19.
Robertson NJFatal overdose from a sustained-release theophylline preparation. Annals of Emergency Medicine1985; 14: 154-158.
20.
Zwillich CW et al. Theophylline-induced seizures in adults. Correlation with serum concentrations. Annals of Internal Medicine1975; 82: 784-787.
21.
Higgins RM et al. Severe theophylline poisoning: charcoal haemoperfusion or haemodialysis ? Postgraduate Medical Journal1995; 71: 224-226.
22.
Hendeles L. , Massanari M., Weinberger M.Update on the pharmacodynamics and pharmacokinetics of theophylline. Chest1985; 88: (suppl) 103S-111S.
23.
Sessler CNTheophylline toxicity: clinical features of 116 consecutive cases. American Journal of Medicine1990; 88: 567-576.
24.
Weinberger M.The pharmacology and therapeutic use of theophylline . Journal of Allergy and Clinical Immunology1984; 73: 525-540.
25.
Mitenko PA, Ogilvie RIRational intravenous doses of theophylline. New England Journal of Medicine1973; 289: 600-603.
26.
Hendeles L. , Weinberger MM, Bighley L.Disposition of theophylline following a single intravenous infusion of aminophylline. American Review of Respiratory Disease1978; 118: 97-103.
27.
Hendeles L. , Weinberger M.Avoidance of adverse effects during chronic therapy with theophylline. European Journal of Respiratory Disease1980; 61: (suppl 109) 103-119.
28.
Milavetz G. , Vaughan LM, Weinberger MM, Hendeles L.Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma . Journal of Pediatrics1986; 109: 351-354.
29.
Weinberger M., Hendeles SLSlow-release theophylline: Rationale and basis for product selection. New England Journal of Medicine1983; 308: 760-764.
Tsai J. et al. The clinical implication of theophylline intoxication in the emergency department. Human and Experimental Toxicology1994; 13: 651-657.
32.
Paloucek FP , Rodvold KAEvaluation of theophylline overdoses and toxicities . Annals of Emergency Medicine1988; 17: 135-144.
33.
Frewin DB, Cooper DJAccidental coadministration of intravenous aminophylline and theophylline by mouth: a hazardous practice. Medical Journal of Australia1986; 144: 481-482.
Johnston Ida.Controversies in therapeutics: theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications. British Medical Journal1990; 300: 929-931.
36.
Munro CS, Prowse K.Doses of aminophylline given intravenously in casualty department and resulting serum theophylline concentrations. British Medical Journal1984; 289: 354-355.
37.
Stewart MF, Barclay J., Warburton R.Risk of giving intravenous aminophylline to acutely ill patients receiving maintenance treatment with theophylline. British Medical Journal1984; 288: 450.
38.
Howell RE, Muehsam WT, Kinnier WJMechanism for the emetic side effect of xanthine bronchodilators. Life Sciences1990; 46: 563-568.
39.
Gaudreault P., Wason S., Lovejoy Jr FHAcute pediatric theophylline overdose: a summary of 28 cases. Journal of Pediatrics1983; 102: 474-476.
40.
Sessler CN, Glauser FL, Cooper KRTreatment of theophylline toxicity with oral activated charcoal. Chest1985; 87: 325-329.
41.
Andersson KE , Persson Cga.Extrapulmonary effects of theophylline. European Journal of Respiratory Disease1980; 61: (suppl 109) 17-28.
42.
Foster LJ, Trudeau WL, Goldman ALBronchodilator effects on gastric acid secretion. Journal of theAmerican Medical Association1979; 241: 2613-2615.
43.
Johannesson N., Anderson K-E.,Joelsson B., Persson Cga.Relaxation of lower esophageal sphincter and stimulation of gastric secretion and diuresis by antiasthmatic xanthines . American Review of Respiratory Disease1985 ; 131: 26-31.
44.
Amitai Y., Yeung AC, Moye J., Lovejoy FH Jr. Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Annals of Internal Medicine1986; 105: 386-387.
45.
Amitai Y., Lovejoy FH Jr. Characteristics of vomiting associated with sustained release theophylline poisoning: implications for management with oral activated charcoal. Clinical Toxicology1987; 25: 539-544.
46.
Anderson W. , Youl B., Mackay IRAcute theophylline intoxication. Annals of Emergency Medicine1991; 20: 1143-1145.
47.
Parr MJ et al. Theophylline poisoning - a review of 64 cases. Intensive Care Medicine1990; 16: 394-398.
Olson KR, Benowitz NL, Woo OF, Pond SMTheophylline overdose: acute single ingestion versus chronic repeated over-medication . American Journal of Emergency Medicine1985 ; 3: 386-394.
50.
Amitai Y., Mitchell AA, McGuigan MA, Lovejoy FH Jr.Ipecac-induced emesis and reduction of plasma concentrations of drugs following accidental overdose in children. Pediatrics1987; 80: 364-367.
51.
Powell DW, Farris RK, Carbinetto STTheophylline, cyclic AMP, choleragen and electrolyte transport by rabbit ileum . American Journal of Physiology1974; 227: 1428-1435.
52.
Baker MDTheophylline toxicity in children. Journal ofPediatrics1986; 109: 538-542.
53.
Aitken ML, Martin TRLife-threatening theophylline toxicity is not predictable by serum levels . Chest1987; 91: 10-14.
54.
Hall KW et al. Metabolic abnormalities associated with intentional theophylline overdose. Annals of Internal Medicine1984 ; 101: 457-462.
55.
Sessler CN, Cohen MDCardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest1990; 98: 672-678.
56.
Siemons LJ, Parizel G.Prolonged runs of ventricular tachycardia as a complication of theophylline intoxication. Acta Cardiologica1986; 6: 457-464.
57.
Hoford N. et al. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? Clinical Pharmacokinetics1993; 25: 495-505.
58.
Hendeles L. et al. Frequent toxicity from i.v. aminophylline infusions in critically ill patients. Drug Intelligence and Clinical Pharmacy1977; 2: 12-18.
59.
Horowitz LN , Spear JF, Moore EN, Rogers R.Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure. American Journal of Cardiology1975; 35: 376-379.
60.
Biberstein MP, Fiegler MG, Ward DMUse of β-blockade and hemoperfusion for acute theophylline poisoning. Western Journal of Medicine1984; 141: 485-490.
61.
Curry SC, Vance MV, Requa R., Armstead R.The effects of toxic concentrations of theophylline on oxygen consumption, ventricular work, acid base balance and plasma catecholamine levels in the dog. Annals of Emergency Medicine1985; 14: 554-561.
62.
Higbee MD, Kumar M., Galant SPStimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects. Journal of Allergy and Clinical Immunology1982; 70: 377-382.
63.
Vestal RE et al. Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man. Circulation1983; 67: 162-171.
64.
Rutherford JD, Vatner SF, Braunwald E.Effects and mechanism of action of aminophylline on cardiac function and regional blood flow distribution in conscious dogs . Circulation1981; 63: 378-387.
65.
Roden DM, Iansmith Dhs.Effects of low potassium or magnesium concentrations on isolated cardiac muscle . American Journal of Medicine1987; 82: (suppl 3A) 18-23.
66.
Nordrehaug JE, Johannesson K-A., von der Lippe G.Serum potassium concentrations as a risk factor of ventricular arrhythmias early in acute MI. Circulation1985; 71: 645-649.
67.
Stewart DE, Ikram H., Espiner EA, Nichols MGArrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertensive and ischaemic heart disease. British Heart Journal1985; 54: 290-297.
68.
Lim R., Walshaw MJ, Saltissi S., Hind Crk.Cardiac arrhythmias during acute exacerbations of chronic airflow limitation: effect of fall in plasma potassium concentration induced by beta2-agonist therapy. Postgraduate Medical Journal1989 ; 65: 449-452.
69.
Persson CG, Erjefalt L.Seizure activity in animals given enprofylline and theophylline, two xanthines with partly different mechanisms of action. Archives Internationales de Pharmacodynamie et de Therapie1982; 258: 267-282.
70.
Somani SM, Khanna NN, Bada HSCaffeine and theophylline: serum/CSF correlation in premature infants. Journal ofPediatrics1980; 96: 1091-1093.
71.
Jensen MH et al. Is theophylline induced seizures in man caused by inhibition of cerebral 5'nucleotidase activity? Acta Pharmacologica et Toxicologica1984; 55: 331-334.
72.
Dragunow M.Adenosine receptor antagonism accounts for the seizure prolonging effects of aminophylline. Pharmacology, Biochemistry and Behavior1990; 36: 751-755.
73.
Hornfeldt CS , Larson AAAdenosine receptors are not involved in theophylline-induced seizures. Clinical Toxicology1994; 32: 257-265.
74.
Edvinsson L. , Fredholm BBCharacteristics of adenosine receptors in isolated cerebral arteries of cat. BritishJournal of Pharmacology1983; 80: 631-637.
75.
Oberdorster G., Lang R., Zimmer R.Influence of adenosine and lowered cerebral blood flow on the cerebrovascular effects of theophylline. EuropeanJournal of Pharmacology1975; 30: 197-204.
76.
Burkle WS, Gwizdala CJEvaluation of 'toxic' serum theophylline concentrations. American Journal of Hospital Pharmacy1981; 38: 1164-1166.
77.
Covelli HD, Knodel AR, Heppner BTPredisposing factors to apparent theophylline-induced seizures. Annals of Allergy1985; 54: 411-415.
78.
Bahls FH, Ma KK, Bird TDTheophylline-associated seizures with 'therapeutic' or low toxic serum concentrations: Risk factors for serious outcome in adults. Neurology1991; 41: 1309-1312.
79.
Emerman CL, Devlin C., Connors AFRisk of toxicity in patients with elevated theophylline levels. Annals of Emergency Medicine1990; 19: 643-648.
80.
D'Angio R., Sabatelli F.Management considerations in treating metabolic abnormalities associated with theophylline overdose. Archives of Internal Medicine1987; 147: 1837-1838.
81.
Kearney TE, Manoguerra AS, Curtis GP, Ziegler MGTheophylline toxicity and the beta-adrenergic system. Annals of Internal Medicine1985; 102: 766-769.
82.
Sawyer WT, Caravati EM, Ellison MJ, Krueger KAHypokalemia, hyperglycemia and acidosis after intentional theophylline overdose . American Journal of Emergency Medicine1985 ; 3: 408-411.
83.
Church MK et al. Relationships between adenosine, cyclic nucleotides, and xanthines in asthma. Journal of Allergy and Clinical Immunology1986; 78: 670-675.
84.
Poisner AMDirect stimulant effect of aminophylline on catecholamine release from the adrenal medulla. Biochemical Pharmacology1973; 22: 469-476.
85.
Stubbs A., Cushley MJ, Tattersfield AEAttenuation by propranolol of the airway and cardiovascular responses to oral theophylline in normal subjects. Clinical Science1984; 66: 57P.
86.
Brown MJHypokalaemia from beta2-receptor stimulation by circulating epinephrine. American Journal of Cardiology1985; 56: 3D-9D.
87.
Brown MJ, Brown DC, Murphy MBHypokalaemia from beta2-receptor stimulation by circulating epinephrine. New England Journal of Medicine1983; 309: 1414-1419.
88.
Clausen T.Adrenergic control of Na+-K+-homeostasis. Acta Medica Scandinavica1983; 672: (suppl) 111-115.
89.
Clausen T., Flatman JAβ2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. British Journal of Pharmacology1980; 68: 749-755.
90.
Struthers AD , Reid JL, Whitesmith R., Rodger JCThe effects of cardioselective and non-selective β-adrenoceptor blockade on the hypokalaemic and cardiovascular response to adrenomedullary hormones in man. Clinical Science1983; 65: 143-147.
91.
Shannon M., Lovejoy FH Jr. Hypokalemia after theophylline intoxication. The effects of acute vs chronic intoxication. Archives of Internal Medicine1989; 149: 2725-2729.
92.
Shannon M.Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication. Clinical Toxicology1994; 32: 41-47.
93.
Amitai Y., Lovejoy FH Jr. Hypokalaemia in acute theophylline poisoning. American Journal of Emergency Medicine1988; 6: 214-218.
94.
Strubelt O.The influence of reserpine, propranolol and adrenal medullectomy on the hyperglycaemia action of theophylline and caffeine . Archives Internationales de Pharmacodynamie et de Therapie1969; 179: 214-224.
95.
Rasmussen HS et al. Intravenous magnesium in acute myocardial infarction. Lancet1986; 1: 234-235.
96.
Smith LF et al. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. International Journal of Cardiology1986; 12: 175-183.
97.
Teo KK, Yusuf S.Role of magnesium in reducing mortality in acute myocardial infarction. Drugs1993; 46: 347-359.
98.
Chevalier B. et al. Tachycardie ventriculaire au cours d'un surdosage en theophylline. A propos d'un cas de reduction par le chlorure de magnesium. Archives des Maladies du Coeur et des vaisseaux1990; 83: 569-573.
99.
McPherson ML et al. Theophylline-induced hypercalcemia. Annals of Internal Medicine1986; 105: 52-54.
100.
Bernard S.Severe lactic acidosis following theophylline overdose. Annals of Emergency Medicine1991 ; 20: 1135-1137.
101.
Leventhal LJ et al. Lactic acidosis in theophylline overdose . American Journal of Emergency Medicine1989 ; 7: 417-418.
102.
Kolendorf K., Moller BBLactic acidosis in epinephrine poisoning. Acta Medica Scandinavica1974; 196: 465-466.
103.
Madias NE, Goorno WE, Herson S.Severe lactic acidosis as a presenting feature of phaeochromocytoma. American Journal of Kidney Disease1987; 10: 250-253.
104.
Bornemann M., Hill SC, Kidd GSLactic acidosis in phaeochromocytoma. Annals of Internal Medicine1986; 105: 880-882.
105.
Spergel G. , Bleicher SJ, Ertel NHCarbohydrate and fat metabolism in patients with phaeochromocytoma. New England Journal of Medicine1968; 278: 803-809.
106.
Eldridge FL , Millhorn DE, Kiley JPAntagonism by theophylline of respiratory inhibition induced by adenosine. Journal of Applied Physiology1985; 59: 1428-1433.
107.
Oliw E., Anggard E., Fredholm BBEffect of indomethacin on the renal actions of theophylline. EuropeanJournal of Pharmacology1977; 43: 9-16.
108.
Rumpf KW et al. Rhabdomyolysis after theophylline overdose. Lancet1985; 1: 1451-1452.
Parr MJ, Willatts SMFatal theophylline poisoning with rhabdomyolysis. A potential role for dantrolene treatment. Anaesthesia1991; 46: 557-559.
111.
Macdonald JB, Jones HM, Cowan RARhabdomyolysis and acute renal failure after theophylline overdose. Lancet1985; i: 932-933.
112.
Koppel C.Clinical features, pathogenesis and management of drug-induced rhabdomyolysis . Medical Toxicology and Adverse Drug Experience1989; 4: 108-126.
113.
Shannon M.Predictors of major toxicity after theophylline overdose. Annals of Internal Medicine1993 ; 119: 1161-1167.
114.
Grygiel JJ , Wing Lmh, Farkas J., Birkett DJEffect of allopurinol on theophylline metabolism and clearance. Clinical Pharmacology and Therapeutics1979; 36: 660-667.
115.
Campbell ME , Grant DM, Inaba T., Kalow W.Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metabolism and Disposition1987; 15: 237-249.
116.
Robson RA et al. Characterization of theophylline metabolism in human liver microsomes . British Journal of Clinical Pharmacology1987; 24: 293-300.
117.
Robson RA et al. Characterisation of theophylline metabolism by human liver microsomes . Biochemical Pharmacology1988; 37: 1651-1659.
118.
Sarkar MA, Hunt C., Guzelian PS, Karnes T.Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metabolism and Disposition1992; 20: 31-37.
119.
Rall TWDrugs used in the treatment of asthma. The methylxanthines, cromolyn sodium and other agents. In: Goodman and Gilman's The Pharmacological Basis of TherapeuticsGilman AG, Rall TW, Nies AS, Taylor P (eds), 8th edition, McGraw-Hill Inc, 1992; 618-637.
120.
Aranda JV, Turmen T.Methylxanthines in apnea of prematurity. Clin Perinatol1979; 6: 87-108.
121.
Ha HR, Chen J., Freiburghaus AU, Follath F.Metabolism of theophylline by cDNA-expressed human cytochromes P-450. British Journal of Clinical Pharmacology1995; 39: 321-326.
122.
Tucker GTThe rational selection of drug interaction studies: implications of recent advances in drug metabolism. International Journal of Clinical Pharmacology Therapeutics and Toxicology1992; 30: 550-553.
123.
Hurwitz A. et al. Mexiletine effects on theophylline disposition . Clinical Pharmacology and Therapeutics1991 ; 50: 299-307.
124.
Knodell RG et al. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology1991; 101: 1680-1691.
125.
Grygiel JJ , Miners JO, Drew R., Birkett DJDifferential effects of cimetidine on theophylline metabolic pathways. European Journal of Clinical Pharmacology1984; 26: 335-340.
126.
Loi CM, Wei X., Vestal REInhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clinical Pharmacology and Therapeutics1991; 49: 571-580.
127.
Miners JO, Wing Lmh, Lillywhite KJ, Robson RASelective dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. British Journal of Clinical Pharmacology1985; 20: 219-223.
128.
Loi CM, Parker BM, Cusack BJ, Vestal REIndividual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. British Journal of Clinical Pharmacology1993; 36: 195-200.
129.
Conney AHInduction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: GHA Clowes memorial lecture. Cancer Research1982; 42: 4875-4917.
130.
Shimada T. , Iwasawi M., Martin MV, Guengerich FPHuman liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Research1989; 49: 3218-3228.
131.
Rubin E., Lieber CSHepatic microsomal enzymes in man and rat: induction and inhibition by ethanol . Science1969; 169: 690-691.
132.
Wrighton SA et al. Characterization of ethanol inducible human liver N-nitrosodimethylamine demethylase. Biochemistry1986; 25: 6731-6735.
133.
Koop DR, Crump BL, Nordblom GD, Coon MJImmunochemical evidence for induction of the ethanol-oxidizing cytochrome P450 of rabbit liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole and isoniazid. Procedings of theNational Academy of Sciences1985; 82: 4065-4069.
134.
Upton RAPharmacokinetic interactions between theophylline and other medication (Part I). Clinical Pharmacokinetics1991; 20: 66-80.
135.
Upton RAPharmacokinetic interactions between theophylline and other medication (Part II). Clinical Pharmacokinetics1991; 20: 135-150.
136.
Laaban JP et al. Theophylline intoxication following viloxazine induced decrease in clearance. European Journal of Clinical Pharmacology1986; 30: 351-353.
137.
Sperber ADToxic interaction between fluvoxamine and sustained release theophylline in an 11 year old boy. Drug Safety1991; 6: 460-462.
138.
Robson RA, Miners JO, Birkett DJSelective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline. British Journal of Clinical Pharmacology1988; 25: 397-400.
139.
Burnakis TG , Seldon M., Czaplicki ADIncreased serum theophylline concentrations secondary to oral verapamil. Clinical Pharmacy1983; 2: 458-461.
140.
Soto J. et al. Diltiazem treatment impairs theophylline elimination. Therapeutic Drug Monitoring1994; 16: 49-52.
141.
Derby LE et al. Hospital admission for xanthine toxicity. Pharmacotherapy1990; 10: 112-114.
142.
Lin JH et al. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. British Journal of Clinical Pharmacology1987; 24: 669-672.
143.
Vestal RE, Thummel KE, Musser B.Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple dose oral administration. British Journal of Clinical Pharmacology1983; 15: 411-418.
144.
Dal Negro R., Pomari C., Turco P.Famotidine and theophylline pharmacokinetics . Clinical Pharmacokinetics1993; 24: 255-258.
145.
Jusko WJ et al. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. Journal of Pharmaceutical Sciences1979; 68: 1358-1366.
146.
Tornatore KM et al. Effect of chronic oral contraceptive steroids on theophylline disposition. European Journal of Clinical Pharmacology1982; 23: 129-134.
147.
Renton KW, Gray JD, Hung ORDepression of theophylline elimination by erythromycin. Clinical Pharmacology and Therapeutics1981; 30: 422-426.
148.
Zarowitz Bjm , Szefler SJ, Lasezkay GMEffect of erythromycin base on theophylline kinetics. Clinical Pharmacology and Therapeutics1981; 29: 601- 605.
149.
Batty KT et al. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology1995; 39: 305-311.
150.
Manfredi RL , Vesell ESInhibition of theophylline metabolism by long-term allopurinol administration. Clinical Pharmacology and Therapeutics1981; 29: 224-229.
151.
Piafsky KM , Sitar DS, Rangno RE, Ogilvie RITheophylline disposition in patients with hepatic cirrhosis. New England Journal of Medicine1977; 296: 1495-1497.
152.
Guengerich FP, Turvey CGComparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. Journal of Pharmacology and Experimental Therapeutics1991 ; 256: 1189-1191.
153.
Piafsky KM, Sitar DS, Rangno RE, Ogilvie RITheophylline kinetics in acute pulmonary oedema. Clinical Pharmacology and Therapeutics1977; 21: 310-316.
154.
Chang KC, Bell TD, Lauer BA, Chai H.Altered theophylline pharmacokinetics during acute respiratory virus illness . Lancet1978; 1: 1132-1133.
155.
Marquis J-F. et al. Phenytoin-theophylline interaction. New England Journal of Medicine1982; 307: 1189-1190.
156.
Kesler KM et al. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. American Heart Journal1989; 117: 964-966.
157.
Hunt SN, Jusko WJ, Yurchak AMEffects of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics1976; 19: 546.
158.
Powell JR et al. The influence of cigarette smoking and sex on theophylline disposition . American Review of Respiratory Disease1977 ; 116: 17-23.
159.
Troger U., Meyer FPInfluence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Clinical Pharmacokinetics1995 ; 28: 287-314.
160.
Rice KL et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine1987; 107: 305-309.
161.
Prior JG, Berry D., Cochrane GMSerum theophylline concentrations during multiple dosing with two sustained release methyl-xanthine preparations in normal subjects. Postgraduate Medical Journal1980; 56: 638-641.
162.
Anon. Theophylline benefits and difficulties. Lancet1983; 2: 607-608.
163.
Fairshter RD, Busse WWTheophylline - how much is enough?Journal of Allergy and Clinical Immunology1986; 77: 646-648.
164.
Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: A meta analysis. Therapeutic Drug Monitoring1990 ; 12: 72-78.
165.
Travers EMMisuse of therapeutic drug monitoring: An analysis of causes and methods for improvement. Clinics in Laboratory Medicine1987; 7: 453-472.
166.
Jonkman Jhg , Van der Boon Wjv.Nocturnal plasma theophylline concentrations . Lancet1983; 1: 1278-1279.
Mungall D. et al. Individualising theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. Therapeutic Drug Monitoring1983; 5: 95-101.
169.
Kirk JK et al. Salivary theophylline monitoring: reassessment and clinical considerations. Therapeutic Drug Monitoring1994; 16: 58-66.
170.
Weinberger MCTheophylline. PoisindexR Volume 86. 1974-1995; Micromedex Inc, Denver, USA.
171.
Minton NA, Henry JATreatment of theophylline overdose. American Journal of Emergency Medicinen1996 (in press).
172.
Amin DA, Henry JAPropranolol administration in theophylline overdose. Lancet1985; 1: 520-521.
173.
Wiest D. Esmolol.A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet1995; 28: 190-202.
174.
Brown Sga, Prentice DAOndansetron in the treatment of theophylline overdose. Med J Austr1992; 156: 512.
175.
Sage TA, Jones WN, Clark RFOndansetron in the treatment of intractable nausea associated with theophylline toxicity. Ann Pharmacother1993; 27: 584-585.
176.
Greenberg A., Piraino BH, Kroboth PD, Weiss J.Severe theophylline toxicity. Role of conservative measures, antiarrhythmic agents and charcoal hemoperfusion. Am J Med1984; 76: 854-860.
177.
Goldberg MJ , Park GD, Berlinger WGTreatment of theophylline intoxication. J Allergy Clin Immunol1986; 78: 811-817.